New Treatment Could Change Everything
- The provided text discusses Nathalie Allaire, a Montreal resident diagnosed with early-onset Alzheimer's disease, and her access to Leqembi, a recently approved treatment.
- Alzheimer's disease is a progressive neurodegenerative disease that causes brain cells to degenerate and die, leading to a continuous decline in thinking, behavioral and social skills.
- Leqembi (lecanemab) was approved by Health Canada on October 27, 2023, not 2025 as stated in the source text.
Nathalie Allaire and Early-Onset Alzheimer’s Disease
Table of Contents
The provided text discusses Nathalie Allaire, a Montreal resident diagnosed with early-onset Alzheimer’s disease, and her access to Leqembi, a recently approved treatment.
Alzheimer’s Disease
Alzheimer’s disease is a progressive neurodegenerative disease that causes brain cells to degenerate and die, leading to a continuous decline in thinking, behavioral and social skills. The national Institute on Aging identifies it as the most common cause of dementia. Early-onset Alzheimer’s, as in Allaire’s case, is defined as occurring before the age of 65, and represents a smaller percentage of all Alzheimer’s cases. Symptoms can initially be mistaken for other conditions, as highlighted in the text mentioning initial misdiagnosis as pre-menopause or ADHD.
Leqembi (lecanemab) Approval in Canada
Leqembi (lecanemab) was approved by Health Canada on October 27, 2023, not 2025 as stated in the source text. It is indeed indicated for the treatment of early Alzheimer’s disease. the drug is administered via intravenous infusion and targets amyloid plaques,a hallmark of Alzheimer’s disease,in the brain.
Leqembi’s Efficacy
Clinical trials have demonstrated that leqembi can slow the rate of cognitive decline in patients with early Alzheimer’s disease. Eisai, the pharmaceutical company developing Leqembi, reported in January 2023 that the drug slowed cognitive decline by 27% compared to placebo over 18 months in a Phase 3 clinical trial. This aligns with the 27-30% figure mentioned in the original text.
Institut Douglas mental Health University Center
The Institut Douglas Mental health University Centre in Montreal played a role in Allaire’s diagnosis.it is indeed a teaching hospital affiliated with McGill University, specializing in mental health care and research. The text indicates that Allaire received confirmation of her diagnosis at this institute after a MoCA (Montreal Cognitive Assessment) test revealed the extent of her cognitive impairment.
Breaking News Check (2026/01/22 14:35:51): As of today, there have been no major breaking developments regarding Leqembi’s approval status in Canada or significant updates to its efficacy data. Ongoing research continues to explore its long-term effects and potential for broader application. Access to Leqembi remains a topic of discussion regarding provincial healthcare coverage and logistical challenges of intravenous management.